A retrospective analysis of 445 women with germline BRCA1/2 mutations (79% of whom had had breast and/or ovarian cancer) found a non-significant (p = 0.06) reduction in overall survival in those with BRCA1 exon 20 mutations compared to those with mutations in BRCA1 exons 2 or 1119. This evidence concerns the gene BRCA1 and ovarian cancer.